Abstract

FORMULATION AND EVALUATION OF SUMATRIPTAN SUCCINATE AND NAPROXEN SODIUM BI-LAYER TABLETS

Jyothula Mery*, Suryakanta Swain and Manohar Babu S.

ABSTRACT

Sumatriptan succinate is a 5HT1D-Serotonin receptor agonist. It acts as an anti-migraine agent. On oral administration, it is absorbed through GI tract and the bioavailability of Sumatriptan succinate is approximately 15%. It has short biological half-life (2 hours). Naproxen sodium is an NSAID. It possesses analgesic, anti-inflammatory, anti-pyretic properties. On oral administration, it is absorbed through GI tract and absolute bioavailability of Naproxen sodium is approximately 95% and its biological half-life is about 19 hours. The combinations of Sumatriptan succinate and Naproxen sodium have a synergistic effect on migraine headache. The combination of Sumatriptan succinate and Naproxen sodium is not an official formulation. Though there is no combination product available in Indian market, the combination product is approved by FDA and is available in US market. The present investigation relates to the development of a stable dosage form containing both Sumatriptan succinate and Naproxen sodium drugs which are intended for immediate release.

Keywords: Sumatriptan succinate, Naproxen sodium, Anti-migraine agent, synergistic effect, Bilayered Tablets.